High-dose chemotherapy for Ewing Sarcoma and Rhabdomyosarcoma: a systematic review by the Australia and New Zealand Sarcoma Association clinical practice guidelines working party

Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) are small round blue cell tumours that occur in children, adolescents and young adults (AYA) [1 –3]. In ES, the EWSR1-FLI1 fusion is identified in 85% of cases [1,4]. Small round cell sarcomas of bone and soft tissue where EWSR1-FLI1 fusion is not identified were previously collated with ES and termed the Ewing sarcoma family of tumours (ESFT) [1]. Molecular profiling has revealed fusions in cluding EWSR1–non-ETS fusions, CIC-rearrangements, and BCOR alterations by which these tumours are now classified and understood to confer different natural histories and treatment sensitivities [5,6].

Source: Cancer Treatment Reviews - February 1, 2024 Category: Cancer & Oncology Authors: Ashika Ramamurthy, Elizabeth A Connolly, Jasmine Mar, Jeremy Lewin, Vivek A Bhadri, Marianne B Phillips, Mark Winstanley, Lisa M Orme, Peter Grimison, Joanna Connor, Smaro Lazarakis, Angela M Hong, Natacha Omer, Julie Cayrol Source Type: research